Frank Damelio Buys 6,650 Shares of Zoetis (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) Director Frank Damelio acquired 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zoetis Trading Up 1.7%

Shares of ZTS stock opened at $75.57 on Friday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock’s fifty day moving average is $113.32 and its two-hundred day moving average is $121.27. Zoetis Inc. has a fifty-two week low of $73.98 and a fifty-two week high of $172.23. The firm has a market capitalization of $31.68 billion, a P/E ratio of 12.53, a PEG ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZTS. J. Stern & Co. LLP boosted its stake in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $734,425,000. Vanguard Group Inc. lifted its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Diamond Hill Capital Management Inc. purchased a new position in Zoetis during the third quarter worth about $394,010,000. Finally, Nordea Investment Management AB boosted its position in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZTS. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup assumed coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. JPMorgan Chase & Co. cut their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and a consensus target price of $141.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.